eIF3β/eIF3I Antibody (A-12): sc-374157
- eIF3β/eIF3I Antibody (A-12) is a mouse monoclonal IgG2a κ provided at 200 µg/ml
- raised against amino acids 1-300 mapping within an internal region of eIF3β of human origin
- recommended for detection of eIF3β of mouse, rat and human origin by WB, IP, IF and ELISA
- m-IgG2a BP-HRP is the preferred secondary detection reagent for eIF3β/eIF3I Antibody (A-12) for WB applications. This reagent is now offered in a bundle with eIF3β/eIF3I Antibody (A-12) (see ordering information below).
eIF3β Antibody (A-12) is a mouse monoclonal IgG2a antibody that detects eIF3β in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). eIF3β is a critical component of the eukaryotic initiation factor 3 complex, which plays a pivotal role in protein synthesis regulation by facilitating 40S ribosomal subunit assembly. eIF3β is located in the cytoplasm, where eIF3β interacts with other initiation factors and mRNA to form the pre-initiation complex necessary for translation. Proper localization of eIF3β is essential for efficient protein synthesis, ensuring correct ribosomal subunit assembly and effective translation machinery engagement. Notably, dysregulation of eIF3β expression has been linked to various cancers, highlighting eIF3β′s importance in cellular growth and proliferation. anti-eIF3β antibody (A-12) provides a valuable tool for researchers studying translation initiation mechanisms and cancer biology implications, allowing detailed analysis of eIF3β′s role in both normal and pathological states.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
eIF3β/eIF3I Antibody (A-12) References:
- RNA interference-mediated silencing of eukaryotic translation initiation factor 3, subunit B (EIF3B) gene expression inhibits proliferation of colon cancer cells. | Wang, Z., et al. 2012. World J Surg Oncol. 10: 119. PMID: 22734884
- Novel RNA-binding protein P311 binds eukaryotic translation initiation factor 3 subunit b (eIF3b) to promote translation of transforming growth factor β1-3 (TGF-β1-3). | Yue, MM., et al. 2014. J Biol Chem. 289: 33971-83. PMID: 25336651
- Expression of eukaryotic translation initiation factor 3 subunit B in liver cancer and its prognostic significance. | Yue, Q., et al. 2020. Exp Ther Med. 20: 436-446. PMID: 32537008
- Eukaryotic translation initiation factor 3 subunit b is a novel oncogenic factor in prostate cancer. | Xiang, P., et al. 2020. Mamm Genome. 31: 197-204. PMID: 32556998
- Attenuated diphtheria toxin mediates siRNA delivery. | Arnold, AE., et al. 2020. Sci Adv. 6: PMID: 32917630
- Eukaryotic Translation Initiation Factor 3 Subunit B Is a Promoter in the Development and Progression of Pancreatic Cancer. | Ren, H., et al. 2021. Front Oncol. 11: 644156. PMID: 33996561
- Eukaryotic translation initiation factor 3 subunit B could serve as a potential prognostic predictor for breast cancer. | Song, S., et al. 2022. Bioengineered. 13: 2762-2776. PMID: 35040374
- Eukaryotic translation initiation factor 3 subunit B promotes head and neck cancer via CEBPB translation. | Xu, C., et al. 2022. Cancer Cell Int. 22: 161. PMID: 35459206
- YTHDF2 Is a Therapeutic Target for HCC by Suppressing Immune Evasion and Angiogenesis Through ETV5/PD-L1/VEGFA Axis. | Wen, J., et al. 2024. Adv Sci (Weinh). 11: e2307242. PMID: 38247171
- New TIPARP inhibitor rescues mitochondrial function and brain injury in ischemic stroke. | Cai, Y., et al. 2024. Pharmacol Res. 210: 107508. PMID: 39547463
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
eIF3β/eIF3I Antibody (A-12) | sc-374157 | 200 µg/ml | $322.00 | |||
eIF3β/eIF3I Antibody (A-12): m-IgG2a BP-HRP Bundle | sc-546053 | 200 µg Ab; 10 µg BP | $361.00 |